TTAC-0001 Phase II Trial With Recurrent Glioblastoma Progressed on Bevacizumab
This is a phase II, open-Label clinical trial to evaluate the safety and efficacy of TTAC-0001 in patients with recurrent glioblastoma who was progressed on bevacizumab including therapy.
Recurrent Glioblastoma
DRUG: TTAC-0001
Adverse Events, The frequency and percentage of AEs will be presented by dose goup, until time of progressive disease or 1 year
Progression free survival rate at 4 months, The rate and 2-sided 95% confidence interval of progression free survival at the 4-month, at the end of 4 months|Progression free survival rate at 6 months, The rate and 2-sided 95% confidence interval of progression free survival at the 6-month, at the end of 6 months|Progression free survival, Period from the date of the drug administration to the disease progression time point, until time of progressive disease or time point of patients' death which come first assessed up to 1 year|Overall survival, Period from the date of the drug administration to the time point of patient's death, until time point of patients' death up to 1 year|Objective response rate, complete response (CR) or partial response (PR) by RANO criteria, At every 2nd cycles until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 1 year (every cycle is 28 days)|Disease control rate, complete response (CR), partial response (PR) or stable disease (SD) by RANO criteria, At every 2nd cycles until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 1 year (every cycle is 28 days)
Immunogenicity, Presence anti-drug antibody (ADA), From screening visit to end of treatment visit (time of progressive disease or 1 year)|Pharmacokinetic parameters - Cmax, Maximum concentration of drug by dose level, From screening visit to end of treatment visit (time of progressive disease or 1 year)|Pharmacokinetic parameters - Cmin, Minimum concentration of drug by dose level, From screening visit to end of treatment visit (time of progressive disease or 1 year)|Pharmacokinetic parameters - AUC0-t, Area under the curve from baseline to each timepoint by dose level, From screening visit to end of treatment visit (time of progressive disease or 1 year)|Pharmacokinetic parameters -Tmax, Time of Cmax by dose level, From screening visit to end of treatment visit (time of progressive disease or 1 year)|Pharmacokinetic parameters - CL, Clearance by dose level, From screening visit to end of treatment visit (time of progressive disease or 1 year)|Pharmacokinetic parameters - Vd, Volume of distribution by dose level, From screening visit to end of treatment visit (time of progressive disease or 1 year)|Pharmacokinetic parameters - Ke, Elimination rate constant by dose level, From screening visit to end of treatment visit (time of progressive disease or 1 year)|Pharmacokinetic parameters - TÂ½, Half-life by dose level, From screening visit to end of treatment visit (time of progressive disease or 1 year)|Change in concentration of serum angiogenic factor or receptor, VEGF, placental growth factor \[PLGF\], soluble vascular endothelial growth factor receptor \[sVEGFR\]-2, sVEGFR-1, etc., From screening visit to end of treatment visit (time of progressive disease or 1 year)|DCE-MRI, Blood flow parameter - iAUC, K-trans, Screening visit, on Day8 and Day 15 of cycle 1, Day 28 of every 2nd cycle (1 cycle is 28 days, up to 1 year)
This is a phase II, open-Label clinical trial to evaluate the safety and efficacy of TTAC-0001 in patients with recurrent glioblastoma who was progressed on bevacizumab including therapy.